Molecular and clinical profiling

分子和临床分析

• 批准号: 8157787
• 负责人: Carl Ola Landgren
• 金额: $ 55.15万
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8157787
• 关键词: Clinical; Molecular

If we will provide a better understadning of underlying mechanisms of myelomagenesis, then we will be able to reach are goals to (1) define high-risk precursor disease patinets, and to (2) delay and prevent development of multiple myeloma. For example, in 2010, we have developed the first treatment study for smoldering myeloma in the world, using a novel treatment approach; we are planning on using a new modality (a monoclonal antibody which targets natural killer cells, which in turn will cause anti-myeloma effect). If we will be able to reach our goals that will have a major impact on the clinical management and outcome of multiple myeloma in the future.

如果我们能够更好地理解骨髓瘤形成的潜在机制，那么我们将能够达到我们的目标：(1)定义高风险的前驱疾病患者，(2)延迟和预防多发性骨髓瘤的发展。例如，在2010年，我们开发了世界上第一个针对阴燃骨髓瘤的治疗研究，使用了一种新的治疗方法；我们正计划使用一种新的方式（一种针对自然杀伤细胞的单克隆抗体，它反过来会产生抗骨髓瘤的效果）。如果我们能够达到我们的目标，这将对未来多发性骨髓瘤的临床管理和结果产生重大影响。